What is it about?
Testing the efficacy of melatonin as a cardioprotective therapy in pulmonary hypertension (PH). Due to the marginal success with current PH treatments, researchers are now developing cardioprotective therapies that can be given in adjunction to current PH treatments, with the hope of increasing patient survival and quality of life. Therefore, we tested the whether melatonin can achieve this goal.
Featured Image
Why is it important?
If melatonin is successful, we can test it in clinical trials with the hope of proving improved therapy for patients with PH.
Perspectives
The potential use of melatonin as a cardioprotective and disease mitigating agent is backed up by decades of scientific evidence. Melatonin has been proven to be extremely effective, with little or almost no side effects and it is affordable. Considering the great expense of current PH treatments, melatonin provides a great opportunity for PH patients in low income countries.
Dr Gerald Jerome Maarman
University of Cape Town
Read the Original
This page is a summary of: Melatonin as a preventive and curative therapy against pulmonary hypertension, Journal of Pineal Research, August 2015, Wiley,
DOI: 10.1111/jpi.12263.
You can read the full text:
Contributors
The following have contributed to this page
